Exagen Inc
XGN6.630USD
+0.200+3.11%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
149.24MMarket Cap
LossP/E TTM
More Details of Exagen Inc Company
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Exagen Inc Info
Ticker SymbolXGN
Company nameExagen Inc
IPO dateSep 19, 2019
CEOAballi (John)
Number of employees203
Security typeOrdinary Share
Fiscal year-endSep 19
Address1261 Liberty Way
CityVISTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92081
Phone17605601501
Websitehttps://exagen.com/
Ticker SymbolXGN
IPO dateSep 19, 2019
CEOAballi (John)
Company Executives of Exagen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Aballi
Mr. John Aballi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
336.08K
-8.64%
Dr. Tina Susan Nova, Ph.D.
Dr. Tina Susan Nova, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
54.11K
--
Ms. Ana Hooker
Ms. Ana Hooker
Independent Director
Independent Director
33.00K
--
Mr. Frank Stokes
Mr. Frank Stokes
Independent Director
Independent Director
33.00K
--
Mr. Jeffrey G. (Jeff) Black
Mr. Jeffrey G. (Jeff) Black
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
29.03K
-41.35%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Independent Director
Independent Director
8.33K
--
Dr. Scott D. Kahn, Ph.D.
Dr. Scott D. Kahn, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles S. (Chas) Mckhann
Mr. Charles S. (Chas) Mckhann
Independent Director
Independent Director
--
--
Dr. Bruce C. Robertson, Ph.D.
Dr. Bruce C. Robertson, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Aballi
Mr. John Aballi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
336.08K
-8.64%
Dr. Tina Susan Nova, Ph.D.
Dr. Tina Susan Nova, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
54.11K
--
Ms. Ana Hooker
Ms. Ana Hooker
Independent Director
Independent Director
33.00K
--
Mr. Frank Stokes
Mr. Frank Stokes
Independent Director
Independent Director
33.00K
--
Mr. Jeffrey G. (Jeff) Black
Mr. Jeffrey G. (Jeff) Black
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
29.03K
-41.35%
Mr. Paul Kim, CPA
Mr. Paul Kim, CPA
Independent Director
Independent Director
8.33K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Commercial
8.81M
51.22%
Client
4.37M
25.41%
Government
3.93M
22.82%
Other
94.00K
0.55%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Commercial
8.81M
51.22%
Client
4.37M
25.41%
Government
3.93M
22.82%
Other
94.00K
0.55%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tullis Health Investors
7.97%
NMSIC Co-Investment Fund, L.P
7.76%
RTW Investments L.P.
7.49%
H.I.G. Capital, LLC
7.48%
Hunt Holdings, L.P
3.66%
Other
65.64%
Shareholders
Shareholders
Proportion
Tullis Health Investors
7.97%
NMSIC Co-Investment Fund, L.P
7.76%
RTW Investments L.P.
7.49%
H.I.G. Capital, LLC
7.48%
Hunt Holdings, L.P
3.66%
Other
65.64%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
14.51%
Investment Advisor
12.82%
Corporation
11.42%
Hedge Fund
10.94%
Venture Capital
8.09%
Private Equity
7.48%
Individual Investor
3.19%
Research Firm
1.56%
Pension Fund
0.62%
Other
29.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
94
13.30M
58.71%
+2.23M
2025Q2
80
14.11M
64.13%
-1.92M
2025Q1
76
14.50M
73.21%
-473.27K
2024Q4
75
14.52M
82.35%
-157.43K
2024Q3
78
15.24M
87.35%
-674.41K
2024Q2
89
14.88M
85.44%
-1.05M
2024Q1
115
14.74M
85.49%
-1.97M
2023Q4
122
14.89M
86.95%
-2.20M
2023Q3
127
15.02M
89.43%
-2.41M
2023Q2
130
15.02M
89.64%
-2.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tullis Health Investors
1.81M
8.21%
--
--
Apr 15, 2025
NMSIC Co-Investment Fund, L.P
1.76M
7.99%
-350.00K
-16.60%
Mar 25, 2025
RTW Investments L.P.
1.70M
7.71%
+185.00K
+12.24%
Jun 30, 2025
H.I.G. Capital, LLC
1.70M
7.71%
--
--
Apr 15, 2025
Hunt Holdings, L.P
829.28K
3.77%
-182.04K
-18.00%
Dec 12, 2024
The Vanguard Group, Inc.
681.62K
3.1%
+190.68K
+38.84%
Jun 30, 2025
Balyasny Asset Management LP
718.78K
3.27%
+718.78K
--
Jun 30, 2025
Kennedy Capital Management LLC
310.72K
1.41%
+15.57K
+5.27%
Jun 30, 2025
Silvercrest Asset Management Group LLC
531.77K
2.42%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
1.13%
Invesco NASDAQ Future Gen 200 ETF
0.64%
Lattice Hartford Multifactor Small Cap ETF
0.37%
iShares Micro-Cap ETF
0.03%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion1.13%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.64%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.03%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Exagen Inc?
The top five shareholders of Exagen Inc are:
Tullis Health Investors holds 1.81M shares, accounting for 8.21% of the total shares.
NMSIC Co-Investment Fund, L.P holds 1.76M shares, accounting for 7.99% of the total shares.
RTW Investments L.P. holds 1.70M shares, accounting for 7.71% of the total shares.
H.I.G. Capital, LLC holds 1.70M shares, accounting for 7.71% of the total shares.
Hunt Holdings, L.P holds 829.28K shares, accounting for 3.77% of the total shares.
Tullis Health Investors holds 1.81M shares, accounting for 8.21% of the total shares.
NMSIC Co-Investment Fund, L.P holds 1.76M shares, accounting for 7.99% of the total shares.
RTW Investments L.P. holds 1.70M shares, accounting for 7.71% of the total shares.
H.I.G. Capital, LLC holds 1.70M shares, accounting for 7.71% of the total shares.
Hunt Holdings, L.P holds 829.28K shares, accounting for 3.77% of the total shares.
What are the top three shareholder types of Exagen Inc?
The top three shareholder types of Exagen Inc are:
Tullis Health Investors
NMSIC Co-Investment Fund, L.P
RTW Investments L.P.
Tullis Health Investors
NMSIC Co-Investment Fund, L.P
RTW Investments L.P.
How many institutions hold shares of Exagen Inc (XGN)?
As of 2025Q3, 94 institutions hold shares of Exagen Inc, with a combined market value of approximately 13.30M, accounting for 58.71% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.42%.
What is the biggest source of revenue for Exagen Inc?
In FY2025Q2, the Commercial business generated the highest revenue for Exagen Inc, amounting to 8.81M and accounting for 51.22% of total revenue.
